← Patent-cliff monitor small molecule LIVDELZI SELADELPAR LYSINE
Loss of exclusivity March 2035 latest FDA-listed patent expiry
Drug detail Brand name LIVDELZI Active ingredient SELADELPAR LYSINE Strength EQ 10MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval August 2024 Marketing status RX
Listed patents Patent Expires Type 11596614 March 2035 use U-1854 11406611 March 2035 use U-1854 10272058 March 2035 use U-1854 9486428 March 2035 use U-1854 7709682 September 2026 substance 7301050 August 2026 substance, product
Regulatory exclusivity Code Expires ODE-486 August 2031 NCE August 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.